TTN and cutaneous squamous cell carcinoma: TTN mutation was identified as a predictor of improved objective response rate to immune checkpoint blockade immunotherapy in seven public clinical cohorts, including advanced cases of cutaneous squamous cell carcinoma, stomach adenocarcinoma, skin cutaneous melanoma, and lung cancer (43).